Background- Paris

New Methods of Collaboration in AI and Data Science

As Early Innovation Partnering Lead for France, Siau Bai tells us more about Johnson & Johnson Innovation’s activities in the region. She discusses how new models of collaboration in the innovation ecosystem, particularly the company's new research collaboration, have the potential to change the trajectory of human health for the better.

Siau Bai

Since 2013, Johnson & Johnson Innovation in EMEA has invested in over 155 collaborations, with JLABS in Belgium incubating 27 companies. JJDC, our strategic venture capital arm, has over 40 companies in its active portfolio. While these statistics showcase the strength of healthcare innovation in the EMEA region, France itself can point to a number of world-class life sciences innovation. In the last three years, we have entered into eight collaborations with innovators and researchers in the French ecosystem, bringing together insightful minds, science, and technology across pharmaceuticals, medical devices and consumer health.

France is one of the top ten largest economies in the world.[1] The country is a major player in global health. Between 2018 and 2020, French companies were some of the most successful in the world in raising a large amount of funds in health-tech.[2]

We are proud that through a new research collaboration, we will be utilising artificial intelligence (AI) and genomics in advancing healthcare solutions. Our approach to AI and genomics as a company is fully aligned with the French government’s stated ambition to become a world leader in health data sharing and management for the common good.

We know that the biggest scientific challenges cannot be solved in isolation, so the collaboration is a joint effort between our Pharmaceutical division, Janssen’s Discovery Computational Sciences team and Immunology therapeutic area, Institut Pasteur, and Greater Paris University Hospitals (APHP). Through harnessing the convergence of AI, biological samples and genomic data, we are aiming to better understand disease biology so we can discover new therapies for patients and deliver a meaningful impact.

By undertaking multi-omics studies with patient bio-samples and associated detailed phenotypic data and in-depth molecular characterisation, this collaboration will offer the opportunity to gain insights into disease biology aimed at transforming the way inflammatory joint disease is treated.  We also have the potential to generate a deeper understanding of the signalling pathways involved in chronic inflammatory diseases.

Using AI and data science in healthcare will transform our society. By making use of these new tools and by collaborating with key opinion leaders, we hope to gain more understanding about the course of disease, so we can try to diagnose, treat, and ultimately attempt to prevent life-changing medical conditions.

You can find out more about the collaboration here.

[1]https://www.who.int/about/funding/contributors/fra

[2]http://www.france-biotech.fr/wp-content/uploads/2021/02/pano-2020-final.pdf